With the acquisition, Castle expects to make available the most comprehensive molecular testing offering for difficult-to-diagnose melanocytic lesions.Continue reading
Author Archive: AZBio
Amid Humanitarian Crisis in India, Merck Announces Voluntary Licensing Agreements with Five Indian Generics Manufacturers to Accelerate and Expand Global Access to Molnupiravir, an Investigational Oral Therapeutic for the Treatment of COVID-19
Merck will also donate more than $5 million in supplies and equipment to aid relief efforts in IndiaContinue reading
GlobalMed Provides Support to Nonprofit Healthcare Organizations for $250M FCC COVID-19 Telehealth Funding
Eligible providers can source the virtual care technology solutions they need for application submission
Gilead Sciences Announces Steps to Expand Availability of Remdesivir in India
– Gilead Will Donate a Minimum of 450,000 Vials of Veklury® to the Government of India –
– Company Will Continue to Support Expansion of Local Production Capacity –
Artificial Intelligence could create better outcomes for bowel cancer patients
A test which uses artificial intelligence (AI) to measure proteins present in some patients with advanced bowel cancer could hold the key to more targeted treatment, according to new research.
A team at the University of Leeds collaborated with researchers at Roche Diagnostics to develop the technique, which could help doctors and patients to decide on the best treatment options.Continue reading
Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy
- About 90,000 women globally die from endometrial cancer each year1
- VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI (dostarlimab-gxly)
- Roche/GSK collaboration represents an important step towards a personalised healthcare strategy that can help identify patients who are most likely to benefit from a specific therapy
Johnson & Johnson Single-Shot COVID-19 Vaccine Phase 3 Data Published in New England Journal of Medicine
- Single-dose vaccine prevented hospitalization and death across all study participants, 28 days after vaccination
- Vaccine shown to be effective against severe/critical COVID-19 disease as early as seven days after vaccination, with efficacy continuing to increase eight weeks post-vaccination
- Vaccine also shown to be consistently effective against symptomatic infection, including in South Africa and Brazil where there was a high prevalence of rapidly emerging SARS-CoV-2 variants
BD Announces 510(k) Clearance of Pristine™ Long-Term Hemodialysis Catheter
Clearance supported by clinical data from a feasibility study with favorable primary patency rates observed out to 180 days Pristine™ Long-Term Hemodialysis Catheter
Arizona’s bioscience community reports on ‘a robust industry cluster’
The Flinn Foundation hosted its annual bioscience event April 14 to share the impressive progress of Arizona’s growing sector nearly two decades since the launch of Arizona’s Bioscience Roadmap.
The virtual event featured a keynote address by Tom Osha of Wexford Science and Technology and a mix of live presentations and videos showcasing the innovative and growing bioscience ecosystem throughout Arizona, including Flagstaff, metro Phoenix, and the Tucson and Yuma regions. Continue reading
FCC to Award Additional $250M in Funding COVID-19 Telehealth Program
Applications for the 2021 FCC Telehealth Program are expected to open soon. Life365 is providing information and resources to help qualified healthcare organizations get started with their applications.
Continue reading